Hu (Human), Ms (Mouse), Rt (Rat), Bov (Bovine), Mky (Monkey)
Paraffin Sections (P), Western blot / Immunoblot (WB), Enzyme Immunoassay (E)
Background of Melatonin Receptor 1B antibody
Melatonin (N-acetyl-5-methoxytryptamine) is a product of tryptophan metabolism. It is synthesized in the pineal gland and is secreted to control the circadian rhythm. Melatonin is also synthesized in the gastrointestil tract, reti, skin and other tissues where it acts in a autocrine or paracrine manner. The role of melatonin in these tissues is independent of its role in the circadian rhythm, where it plays a role in energy metabolism, physiological growth, differentiation and responsiveness in stress stimuli. The pleiotropic effects of melatonin have given rise to various therapeutic possibilities for this molecule. For example; anti-stress, sexual dysfunction, obesity, gallbladder stones. To date, the only therapeutic uses for melatonin remain to treat sleep disorders, depression, migraine and headaches. Melatonin exerts its effects through two G-protein coupled receptors (GPCRs); melatonin receptor type 1 and melatonin receptor type 2 (MT1 and MT2). Like all GPCRs, they have seven transmembrane domains and extracellular N-termil and cytoplasmic C-termil tails. The binding of melatonin to either receptor activates Gi, thereby activating PLC, thus increasing intracellular Ca2+ levels. Both receptors structurally bind melatonin in the same manner, although MT2 displays a much higher affinity for the hormone. Just like melatonin levels are detected in many tissues, the expression patterns of the two receptors are also quite broad. For example, MT1 is detected in the brain, reti and kidneys and MT2 is expressed in brain and in the reti. MT1 is involved in sleep regulation and might also have effects on peripheral vasoconstriction. MT2 may play an important physiological role in the reti and might regulate body temperature.
Immunohistochemical staining of Brain using anti- MTNR1B antibody SP4390P
Western Blot: Melatonin Receptor 1B Antibody [NBP1-84983] Lane 1: Marker [kDa] 250, 130, 95, 72, 55, 36, 28, 17, 10 | Lane 2: Negative control (vector only transfected HEK293T lysate) | Lane 3: Over-expression Lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells.
Western blot analysis of mouse (lanes 1 and 3) and rat (lanes 2 and 4) brain lysates: 1,2. Anti-Melatonin Receptor Type 2 antibody, (1:200). 3,4. Anti-Melatonin Receptor Type 2 antibody, preincubated with the control peptide antigen.
IHC staining of rat paraventricular nucleus sections using Anti-Melatonin Receptor Type 2 antibody , (1:600) and guinea pig Anti-NaV1.2 antibody, (1:2000). A. Melatonin Receptor Type 2 staining (red) (arrows). B. The same section labeled for NaV1.2 (green). C. Merge of A and B demonstrates partial co-localization of Melatonin Receptor Type 2 and NaV1.2 in the paraventricular nucleus (PVN). For orientation, note location with respect to the third ventricle (3rd V).
IHC staining of perfusion-fixed frozen brain sections using Anti-Melatonin Receptor Type 2 antibody, (1:600) and Anti-Angiotensin II Receptor Type-2 (extracellular)-ATTO-488, (1:100). A. Melatonin Receptor Type 2 staining (red) (arrows). B. The same section labeled for Angiotensin II Receptor Type-2 (green). C. Merge of the two images suggests considerable co-localization in the paraventricular nucleus (arrows). For orientation, note localization with respect to 3rd ventricle (3rd V).
Expression of Melatonin receptor type 2 in rat supraoptic nucleus. Immunohistochemical staining of perfusion-fixed frozen brain sections using Anti-Melatonin Receptor Type 2 antibody, (1:600), (red). Melatonin Receptor Type 2 is expressed discretely in the supraoptic nucleus (SON), adjacent to the optric tract (OT). DAPI is used as the counterstain (blue).